Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
E coli vaccine 1 Dose A · 1 trial · 1 indication
Prespecified local reactions (redness, swelling, and pain at the injection site) following each vaccination
Prespecified systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, joint pain, and muscle pain) following each vaccination
Adverse events occurring up to 1 month after the last dose of study intervention
MAEs occurring up to 12 months after the last dose of study intervention
SAEs occurring up to 12 months after the last dose of study intervention
| Arm | Type | Description |
|---|---|---|
| E coli vaccine 1 Dose A | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli vaccine 1 Dose B | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli vaccine 2 | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli vaccine 3 | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 4 Dose A | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 4 Dose B | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 4 Dose C | EXPERIMENTAL | Candidate E coli vaccine on day 1 and day 180 |
| E coli Vaccine 5 Dose A | EXPERIMENTAL | - |
| E coli Vaccine 5 Dose B | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | Placebo received on day 1 and day 180 |
| Name | Type | Description |
|---|---|---|
| E coli vaccine 1 Dose A | DRUG | Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval |
| E coli vaccine 1 Dose B | DRUG | Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval |
| E coli vaccine 2 | DRUG | Candidate E coli vaccine 2, administered according to a 0, 6-month interval |
| E coli vaccine 3 | DRUG | Candidate E coli vaccine 3, administered according to a 0, 6-month interval |
| E coli Vaccine 4 Dose A | DRUG | Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval |
| E coli Vaccine 4 Dose B | DRUG | Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval |
| E coli Vaccine 4 Dose C | DRUG | Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval |
| E coli Vaccine 5 Dose A | DRUG | Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval |
| E coli Vaccine 5 Dose B | DRUG | Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval |
| Placebo | DRUG | Placebo administered according to a 0, 6-month interval |
Ages Eligible for Study: 18 to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Key Inclusion Criteria 1. Adult Participants \>= 18 through \< 64 years of age at the time of enrollment. 2. Healthy participants as determined by medical history, physical examination, an...
E coli vaccine 1 Dose A is an investigational vaccine being studied for use in healthy participants. It is currently in Phase 1 clinical development, with an ongoing trial evaluating its safety and immunogenicity in healthy adults aged 18 years and older in the United States.
E coli vaccine 1 Dose A is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting a Phase 1 clinical trial to evaluate the vaccine in healthy adult participants.
E coli vaccine 1 Dose A is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to assess the vaccine's safety and immune response in healthy adults.
E coli vaccine 1 Dose A is being studied in a Phase 1 clinical trial with the identifier NCT07122986, titled "A Study to Learn About a Vaccine Against E Coli in Healthy Adults." This randomized, double-blind, controlled trial is recruiting 310 healthy participants in the United States.
Yes, E coli vaccine 1 Dose A is classified as a small molecule modality. It is being developed as a vaccine against E. coli and is currently in Phase 1 clinical testing in healthy adult participants.